Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $1.0 billion.

  • Rxo's Total Current Liabilities fell 253.52% to $1.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.0 billion, marking a year-over-year decrease of 253.52%. This contributed to the annual value of $1.0 billion for FY2025, which is 253.52% down from last year.
  • According to the latest figures from Q4 2025, Rxo's Total Current Liabilities is $1.0 billion, which was down 253.52% from $907.0 million recorded in Q3 2025.
  • Over the past 5 years, Rxo's Total Current Liabilities peaked at $1.1 billion during Q4 2024, and registered a low of $662.0 million during Q2 2024.
  • Its 5-year average for Total Current Liabilities is $839.5 million, with a median of $823.0 million in 2022.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 1801.8% in 2023, then skyrocketed by 5615.84% in 2024.
  • Rxo's Total Current Liabilities (Quarter) stood at $816.0 million in 2021, then grew by 0.86% to $823.0 million in 2022, then decreased by 17.13% to $682.0 million in 2023, then soared by 56.16% to $1.1 billion in 2024, then decreased by 2.54% to $1.0 billion in 2025.
  • Its last three reported values are $1.0 billion in Q4 2025, $907.0 million for Q3 2025, and $880.0 million during Q2 2025.